<DOC>
	<DOCNO>NCT00171977</DOCNO>
	<brief_summary>This multicenter , post-marketing , clinical study evaluate safety efficacy postoperative adjuvant therapy Imatinib Mesylate high-risk patient curative resection newly diagnose GIST.Patients evaluate relapse -free survival measure confirmation tumor recurrence survival 3 year surgery primary tumor .</brief_summary>
	<brief_title>Post-Marketing Clinical Study Postoperative Adjuvant Therapy With Imatinib Mesylate Patients With Gastrointestinal Stromal Tumors ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>underwent macroscopically curative resection ; immunohistochemically confirm KIT ( CD117 ) positive tumor ; judge highrisk accord criterion risk classification synchronous double cancer metachronous double cancer diseasefree period â‰¤5 year ; receive therapy Imatinib Mesylate prior study entry ; cardiac problem Grade 3 high ( New York Heart Association ( NYHA ) criterion ) Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>GIST</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Postoperative Adjuvant</keyword>
</DOC>